Literature DB >> 17943598

Expression of PLK1 and survivin in diffuse large B-cell lymphoma.

Lin Liu1, Min Zhang, Ping Zou.   

Abstract

Polo-like kinase 1 (PLK1) belongs to a conservative family of serine/threonine kinase and plays an important role in the process of cell cycle. Survivin is a member of inhibitor of apoptosis protein (IAP) family. We investigated the expression of PLK1 and survivin with immunohistochemical techniques in diffuse large B-cell lymphoma (DLBCL) and assessed their significance as a potent new tumor marker. The expression rate of PLK1 and survivin were 66.7% (26/39) and 82.1% (32/39), respectively. PLK1 expression correlated with systemic symptom, LDH level, IPI scores and therapeutic effect in DLBCL, while survivin did not. PLK1 expression correlated with shortened event-free survival (EFS) using the Log-rank test in DLBCL, but survivin did not. Cox regression analysis identified the independent prognostic significance for PLK1. The results suggest that there is a significant relationship between over expression of PLK1, the clinical features and survival time. Compared with survivin, PLK1 seems to be a better independent prognostic factor for DLBCL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17943598     DOI: 10.1080/10428190701615918

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  22 in total

Review 1.  Targeting polo-like kinase 1 in acute myeloid leukemia.

Authors:  Joseph M Brandwein
Journal:  Ther Adv Hematol       Date:  2015-04

2.  Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Sankaranarayanan Kannan; Marisa J L Aitken; Shelley M Herbrich; Leonard S Golfman; Mandy G Hall; Duncan H Mak; Jared K Burks; Guangchun Song; Marina Konopleva; Charles G Mullighan; Joya Chandra; Patrick A Zweidler-McKay
Journal:  Mol Cancer Ther       Date:  2019-06-21       Impact factor: 6.261

Review 3.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 4.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

5.  MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin.

Authors:  Zhisen Shen; Guowen Zhan; Dong Ye; Yuan Ren; Lixin Cheng; Zhenhua Wu; Junming Guo
Journal:  Med Oncol       Date:  2012-01-14       Impact factor: 3.064

6.  Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.

Authors:  Carsten Berges; Manik Chatterjee; Max S Topp; Hermann Einsele
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

7.  Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP.

Authors:  Zdravko Mitrović; Ivana Ilić; Igor Aurer; Sandra Bašić Kinda; Ivo Radman; Snježana Dotlić; Radmila Ajduković; Boris Labar
Journal:  Pathol Oncol Res       Date:  2010-09-18       Impact factor: 3.201

8.  Growth inhibitory effects of DJ-1-small interfering RNA on laryngeal carcinoma Hep-2 cells.

Authors:  Zhisen Shen; Zhen Jiang; Dong Ye; Bingxiu Xiao; Xingang Zhang; Junming Guo
Journal:  Med Oncol       Date:  2010-03-19       Impact factor: 3.064

9.  PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Authors:  Girija Dasmahapatra; Hiral Patel; Tri Nguyen; Elisa Attkisson; Steven Grant
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

10.  Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.

Authors:  Stefanie A Hartsink-Segers; Carla Exalto; Matthew Allen; Daniel Williamson; Steven C Clifford; Martin Horstmann; Huib N Caron; Rob Pieters; Monique L Den Boer
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.